Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. [6] Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically ...
In addition to CRISPR research, the IGI works to advance public understanding of CRISPR and genome engineering and guide the ethical use of these technologies. Free public resources include: CRISPRpedia — a free textbook-style resource for learning about the biology, applications, and ethics of CRISPR and genome editing, with chapters edited ...
Francisco Juan Martínez Mojica [a] (born 5 October 1963) is a Spanish molecular biologist and microbiologist at the University of Alicante in Spain.He is known for his discovery of repetitive, functional DNA sequences in bacteria which he named CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats).
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and open up specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within living organisms.
He was born in Xinhua County, Loudi City, Hunan, in 1984. [10]He Jiankui attended the University of Science and Technology of China for undergraduate studies from 2002 to 2006, and graduated with a major in modern physics in 2006. [10]
Qi obtained his B.S. in physics and math from Tsinghua University, [1] China, Master in physics from UC Berkeley, and PhD in bioengineering from UC Berkeley. [2] During his PhD work at Berkeley, he studied synthetic biology with Adam Arkin, and was the first to explore engineering the CRISPR for targeted gene editing and gene regulation with Jennifer Doudna. [3]
Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University; Co-Founder and Chief Executive Officer of CRISPR Biotechnologies; Co-Founder and Chief Scientific Officer of Ancilia Biosciences; Co-Founder, President and Chief Scientific Officer of TreeCo; and Co ...